BiyaPay analyst: Yaojie Ankang 50 times in 3 months, Hong Kong stock version of "Meme Coin" emerges

According to BlockBeats, on September 16, the stock price of Hong Kong-listed innovative pharmaceutical company Jie Ankang once soared by more than 60% during the session, with a market value of nearly HK$270 billion. Since its listing on June 23, the stock price has soared by more than 50 times in less than three months. It is called the "Hong Kong Stock Version Meme Coin" by the market, and has become a new hot topic of speculation under capital fanaticism. The fuse of the surge in the drug Jie'ankang is that a clinical trial of the core product tiengotinib was approved for clinical implicit permission. This drug is known as "the world's first FGFR inhibitor to enter the clinical stage of registration", and the market has huge room for imagination. However, the company has no commercial products yet, with a cumulative loss of 870 million yuan in three years, and still has no revenue in the first half of 2025. Its "100 billion market value" is more like the story-driven of Meme coins in the crypto market, lacking fundamental support. BiyaPay analysts pointed out that the trend of Yaojie Ankang is quite similar to that of Meme coins familiar to the currency circle: the circulation is small, the news is strong, and the emotions drive the influx of funds. Driven by funds, the stock price has risen rapidly in the short term, but whether it can stand firm in the long term is still unknown. For crypto investors, this type of Hong Kong stock "new Meme"-style market is becoming a new speculative battlefield. Through BiyaPay, users can not only trade digital currencies such as BTC and ETH at zero handling fees, but also participate in investment in US and Hong Kong stocks in one-stop, seize "monster stocks" opportunities like drug Jie'ankang, and achieve flexible cross-market allocation.